Skip to main content
Scienza Health
Clinical Intelligence

The Cognitive Screening Gap: What We Found in 12.3 Million Post-Acute Patients

Scienza Health·

75% of cognitive impairment in post-acute care goes undetected. Here’s what the data from 12.3 million patients tells us about why — and what changes when screening is embedded in the clinical workflow.

Last updated: April 2026Reviewed quarterly

This week we published a piece in McKnight's Long-Term Care News on the cognitive screening gap in post-acute care. The short version: an estimated three quarters of cognitive impairment in this setting never gets documented. This post expands on what we found in the longitudinal data behind that claim, and what changes when screening is embedded directly in the clinical workflow instead of bolted onto an already overloaded shift.

The Scale of the Gap

Roughly three out of four residents with cognitive, neurological, or behavioral health conditions in post-acute care never have those conditions documented. That is not a rough estimate pulled from a single study. It is what shows up when you pull apart a longitudinal record of 12.3 million post-acute patients and 27 billion clinical events and compare what the chart says against what the speech, behavior, and trajectory data says.

Major depressive disorder runs at roughly 48 percent prevalence in skilled nursing. The MDS Section D field is checked on far fewer charts. Mild cognitive impairment runs at roughly 35 percent and gets documented as “dementia, unspecified” months or years after the signal first appeared in speech. Parkinson’s disease gets a diagnosis 2 to 4 years after the first detectable voice tremor. These are not edge cases. They are the median resident.

Why Documentation Fails Despite Good Clinical Intent

The field-based screening tools a Director of Nursing actually has access to, for example the MMSE or MoCA, take 10 to 30 minutes per resident and require a trained clinician in the room. A 120-bed facility running those tools at the cadence clinical practice calls for would spend roughly 240 clinician hours per quarter on the screening step alone. That is two full-time equivalents dedicated to screening, before a single medication review or care conference. No facility has that capacity. None.

So the shift reality wins. The CNA carries 12 to 18 residents. The nurse runs the med pass and the admission paperwork. The Director of Nursing triages the acute problems: a fall, a pressure injury, a family call. Cognitive screening is the step that falls off the list every single day it is not already embedded in the workflow. That is what the McKnight's piece means by a capacity problem. The intent is there. The clock is not.

What Changes With Embedded Screening

A Samsung Health Grade Galaxy device sits on the admission desk. The new resident is handed the tablet during intake, the same moment they would otherwise be answering paperwork questions. GIA® asks six open-ended prompts and listens. Forty seconds of natural speech later, the structured screening result, clinician-ready note, ICD-10 codes, full transcript, and the recorded video are written back to the PointClickCare record in real time. Total resident time at the front end: under 5 minutes.

The clinician review happens on their own cadence, not the resident’s. Only flagged results surface. Average review time per flagged case is under 2 minutes. For an admit cohort of eight residents per week, the total clinician time spent on screening collapses from the quarterly 240-hour figure above to roughly 5 minutes per week. That is the math that lets a facility actually screen every admission, instead of screening the ones they have time for.

The speech biomarker engine behind the screening analyzes 2,500 acoustic and linguistic signals per session, including pause ratio, speech rate, vocal energy, pitch variability, semantic coherence, and word-finding patterns. Those signals are clinically associated with cognitive decline, depression, anxiety, PTSD, Parkinson’s, and further neurological conditions. Accuracy is peer-reviewed and clinically validated: 81.6 percent on depression, 80.0 percent on PTSD, 77.5 percent on anxiety, AUC 0.97 on Parkinson’s. Full clinical research page lists the 19 peer-reviewed studies behind those figures.

What Changes at the Facility P&L

Undetected cognitive impairment carries a direct dollar cost. Untreated depression in skilled nursing is associated with higher readmission rates. Late-stage Parkinson’s diagnosis misses the window for medication titration that reduces fall incidence. Tardive dyskinesia that goes unscreened under CMS F-Tag 605 is a citation risk in the next survey. Each of these is a P&L line: readmission penalties for Enhanced Track ACOs, falls liability, survey citation remediation. The screening step upstream is what changes those downstream lines.

Three CPT codes apply to the clinician review step: 96127 for the brief assessment, 96116 for the neurobehavioral status exam, and 99309 for the evaluation and management visit that results from a flagged screening. For facilities that have never billed at this level because they never had the screening infrastructure to support it, the codes convert from unused to a recurring revenue line in the first month of deployment.

About GIA®

GIA® is the FDA-registered Digital Human® built by Scienza Health on top of digitalhumanOS™. GIA® conducts the screening conversation through video, voice, or landline in 92 languages, analyzes 2,500+ speech biomarkers, and delivers a structured, clinician-ready result back to the EHR in real time. Live in the PointClickCare Marketplace. Deployed on Samsung Health Grade Galaxy devices secured by Samsung Knox. GIA® screens. A licensed clinician reviews and approves every result before it enters the clinical record. GIA® screens for 24 conditions today, with 22 in development.

Frequently asked questions

What is the cognitive screening gap in post-acute care?

The cognitive screening gap is the systematic under-documentation of cognitive, neurological, and behavioral health conditions in post-acute and long-term care settings. Approximately three out of four residents with these conditions never have them documented. The gap is driven by clinical capacity constraints, not lack of clinical judgment.

How does GIA® close the gap?

GIA® conducts a 40-second natural speech screening on a Samsung Health Grade Galaxy device during intake. The speech biomarker engine analyzes 2,500+ signals and writes structured results, notes, ICD-10 codes, transcripts, and video back to the PointClickCare EHR in real time. Clinician review is under 2 minutes per flagged case.

What conditions does GIA® screen for?

GIA® screens for 24 conditions today, with 22 in development. Current conditions include major depressive disorder, generalized anxiety disorder, PTSD, mild cognitive impairment, Alzheimer’s disease, Parkinson’s disease, and tardive dyskinesia.

What is the evidence base?

digitalhumanOS™ is trained on 12.3 million longitudinal PAC/LTC patient records and 27 billion clinical events. Validation spans 19 peer-reviewed studies across Beth Israel Deaconess Medical Center, NIH, MIT, UC San Diego School of Medicine, and Harvard Medical School. Full list: clinical research page.

What CPT codes apply?

Three CPT codes apply to the clinician review step: 96127, 96116, and 99309. Facilities that lacked the screening infrastructure to generate billable review events can convert these codes from unused to a recurring revenue line within the first month.

What does CMS F-Tag 605 require?

F-Tag 605 covers psychotropic medication oversight and chemical restraints. F-Tag 758 was consolidated into F605 effective April 28, 2025. Tardive dyskinesia screening is a direct F605 compliance concern; facilities that do not screen at the cadence the regulation implies face citation risk in the next survey.

Sources & references

  1. Scienza Health. The Cognitive Screening Gap No One Talks About. McKnight's Long-Term Care News, April 16, 2026.
  2. Advancing Parkinson’s Detection with Vocal Biomarkers and Speech Foundation Models. AUC 0.97 for Parkinson’s detection from conversational speech. Peer-reviewed, published August 2025.
  3. Detecting Mild Cognitive Impairment using Vocal Biomarkers from Spontaneous Speech. Peer-reviewed, September 2024.
  4. Mild Cognitive Impairment Detection via Voice Analysis. Validated approach to early MCI detection addressing a condition commonly missed in primary care. Peer-reviewed, January 2023.
  5. Behavioral Health Assessment Using Vocal Biomarkers. Machine learning models trained on spontaneous speech as an effective first step in identifying individuals at risk. Peer-reviewed, January 2026.
  6. Audio-based Detection of Anxiety and Depression via Vocal Biomarkers. Reliable audio-based detection of both anxiety and depression through vocal biomarker analysis. Peer-reviewed, September 2023.
  7. Full peer-reviewed validation set — 19 studies from Beth Israel Deaconess Medical Center, NIH, MIT, UC San Diego School of Medicine, and Harvard Medical School: scienzahealth.com/research.

See GIA® Screen Live

40 seconds of speech. Results in your EHR.

Schedule a Demo